Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients | Zendy

Daniela Schiesser | Zendy; Isabelle Binet | Zendy; Dimitrios Tsinalis | Zendy; Michael Dickenmann | Zendy; Gérald Keusch | Zendy; Markus Schmidli | Zendy; Patrice M. Ambühl | Zendy; Liudmila Lüthi | Zendy; Rudolf P. Wüthrich | Zendy

Open Access

Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients

Author(s) -

Daniela Schiesser,

Isabelle Binet,

Dimitrios Tsinalis,

Michael Dickenmann,

Gérald Keusch,

Markus Schmidli,

Patrice M. Ambühl,

Liudmila Lüthi,

Rudolf P. Wüthrich

Publication year - 2006

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfl419

Subject(s) - iron sucrose , medicine , transferrin saturation , epoetin alfa , erythropoietin , ferritin , hemodialysis , anemia , dosing , prospective cohort study , darbepoetin alfa , gastroenterology , iron deficiency , transferrin , surgery , intravenous iron

Haemodialysis patients need sustained treatment with intravenous iron because iron deficiency limits the efficacy of recombinant human epoetin therapy in these patients. However, the optimal intravenous iron maintenance dose has not been established yet.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research